Summary
Daily treatment for 1 year of young nulliparous C3H/HeJ mice with 2-bromo-α-ergocryptine (CB-154), an efficacious inhibitor of prolactin secretion, markedly suppressed mammary hyperplastic alveolar nodular development and virtually eliminated the appearance of mammary tumors.
Mature multiparous C3H/HeJ mice treated similarly also had reduced numbers of hyperplastic alveolar nodules and decreased mammary tumor incidence, but the response to the ergot was not as striking as that observed in the younger nulliparous mice. 2-Bromo-α-ergocryptine treatment was, however, generally ineffective in promoting regression of palpable mammary tumors in mature multiparous C3H/HeJ mice. Treatment with 2-bromo-α-ergocryptine had no significant effect on pituitary, ovarian, uterine, adrenal, or body weight, nor did it alter the estrous cycles.
The results of this study suggest that prolactin is an important, perhaps essential, hormone in the developmental phases of mouse mammary tumorigenesis. However, this hormone is of considerably less importance in the more advanced stages of the disease.
Upon the establishment of the hormone as a prerequisite for the development of human breast cancers, the use of appropriate drug-mediated hormone suppression as a prophylactic treatment for the disease may become feasible.
See also:
- Official Web Site: The Di Bella Method;
- The Di Bella Method (A Fixed Part - Bromocriptine and/or Cabergoline);
- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;
- Publication: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor (from Di Bella's Foundation);
- Publication: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);
- About Melatonin - In vitro, review and in vivo publications;
- Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);
- Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);
- Complete objective response to biological therapy of plurifocal breast carcinoma;
- Neuroblastoma: Complete objective response to biological treatment;
- Oesophageal squamocellular carcinoma: a complete and objective response.